THE DEAL, AT A GLANCE
From the announcementSuperluminal Medicines
01Who is involvedBacked by BVF PartnersFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedSuperluminal Medicines raised $60M Series BFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersSuperluminal Medicines’ Series B financing supports a GPCR-focused small-molecule drug discovery strategy centered on endocrine and cardiometabolic diseases, including…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Superluminal Medicines · Financing Record
Explore source-linked visual explanations for Superluminal Medicines. Unsupported claims are withheld while source review continues.
Record 11570 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →